Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:topiramate
|
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
N03AX11
|
| gptkbp:contraindication |
hypersensitivity to topiramate
|
| gptkbp:form |
capsule
extended-release capsule |
| gptkbp:genericName |
topiramate extended-release
|
| https://www.w3.org/2000/01/rdf-schema#label |
Qudexy XR
|
| gptkbp:indication |
epilepsy
migraine prevention |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Upsher-Smith_Laboratories
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
antagonizes AMPA/kainate glutamate receptors
blocks voltage-dependent sodium channels enhances GABA activity inhibits carbonic anhydrase |
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
weight loss drowsiness paresthesia |
| gptkbp:bfsParent |
gptkb:topiramate
|
| gptkbp:bfsLayer |
7
|